On October 23, 2026, Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. The results support the safety and tolerability of ifetroban in this rare disease population. Cumberland Pharmaceuticals Inc. operates as a biopharmaceutical company focused on developing treatments for rare diseases.
